CutisPharma Press Releases Archives - Azurity Pharmaceuticals

Home
News & Events
Careers
Resources
Contact Us

Company
Products
Pipeline
Compounding Kits

Select Page

CutisPharma Announces FIRVANQ™

by GOT | Apr 2, 2018 | CutisPharma Press Releases, News

CutisPharma Announces FIRVANQ™ WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by...

NovaQuest Capital Management Acquires CutisPharma, Inc.

by GOT | Mar 26, 2018 | CutisPharma Press Releases, News

NovaQuest Capital Management Acquires CutisPharma, Inc. WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with...

CutisPharma announces FDA approval of FIRVANQ™

by GOT | Jan 28, 2018 | CutisPharma Press Releases, News

CutisPharma announces FDA approval of FIRVANQ™ CUTISPHARMA ANNOUNCES FDA APPROVAL OF FIRVANQ™ FOR TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (CDAD) AND STAPHYLOCOCCUS AUREUS COLITIS FDA-approved vancomycin oral liquid therapy expected to improve patient...

Search for:

Home

Pipeline

Contact Us

Company

About Us
Management Team
Board of Directors

Products

ADTHYZA^®
BIDIL^®
EDARBI^®
EDARBYCLOR^®
EPANED^®
EPRONTIA^®
EVEKEO^®
EVEKEO ODT^®
FIRVANQ^®
FLEQSUVY^®

GLIADEL^® Wafer
HORIZANT^®
KATERZIA^®
KONVOMEP^®
NYMALIZE^®
QBRELIS^®
SOTYLIZE^®
TRIPTODUR^®
XATMEP^®
ZENZEDI^®
ZONISADE^®

Compounding Kits

FIRST^® – Omeprazole
FIRST^® – Pantoprazole
FIRST^® – Lansoprazole
FIRST^® – BLM Mouthwash
FIRST^® – Metronidazole
FIRST^® – Progesterone

Resources

Azurity Code of Conduct
Azurity Solutions
Azurity Solutions – Patient Direct
E-Z Rx^®
Patient Support
Compliance
Medical Information
Patents & Trademarks

Terms of Use
Privacy Policy and Cookie Notice
Web Accessibility Policy

Product labeling, packaging, and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates. The Information contained herein, including product information, is intended only for residents of the United States.

Sign Up for Email Updates

Share your email to receive information about AZURITY^® and new hypothyroidism resources.

*Fields are required

FIRST NAME(Required)

LAST NAME(Required)

EMAIL ADDRESS

ADDRESS(Required)

ADDRESS LINE 2

CITY*(Required)

STATE*

ZIP CODE(Required)

PHONE NUMBER(Required)

Terms and conditions

By clicking Submit, you agree to receive product and disease state information from Azurity

All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

I accept(Required)

I consent to Azurity Pharmaceuticals, Inc. collecting and storing my data from this form.^†

^†Terms and Conditions must be accepted before submission.

Learn More About AZURITY^®

Learn more about how AZURITY may benefit your patients.

*Fields are required.

FIRST NAME*(Required)

LAST NAME*(Required)

EMAIL ADDRESS*(Required)

ADDRESS LINE 1*(Required)

ADDRESS LINE 2

CITY*(Required)

STATE*(Required)

ZIP CODE*(Required)

PHONE NUMBER*(Required)

Terms and conditions

By clicking Submit, you agree to receive product and disease state information from Azurity Pharmaceuticals, Inc. All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

I Accept(Required)

I consent to Azurity Pharmaceuticals, Inc. collecting and storing my data from this form.^†

^†Terms and Conditions must be accepted before submission.

CutisPharma Announces FIRVANQ™

NovaQuest Capital Management Acquires CutisPharma, Inc.

CutisPharma announces FDA approval of FIRVANQ™

Recent Posts

Recent Comments

Archives

Categories

Meta

Home

Pipeline

Contact Us

Company

Products

Compounding Kits

Resources

Learn More About AZURITY^®

Learn more about how AZURITY may benefit your patients.

Terms and conditions